No association between SNPs regulating TGF-β1 secretion and late radiotherapy toxicity to the breast: results from the RAPPER study.

BACKGROUND AND PURPOSE Several small studies have reported associations between TGFB1 single nucleotide polymorphisms (SNPs), considered to increase secretion of TGF-β1, and greater than 3-fold increases in incidence of fibrosis - an indicator of late toxicity after radiotherapy in breast cancer patients. MATERIALS AND METHODS Two SNPs in TGFB1, C-509T (rs1800469) and L10P (rs1800470), were genotyped in 778 breast cancer patients who had received radiotherapy to the breast. Late radiotherapy toxicity was assessed two years after radiotherapy using a validated photographic technique, clinical assessment and patient questionnaires. RESULTS On photographic assessment, 210 (27%) patients showed some degree of breast shrinkage, whilst 45 (6%) patients showed marked breast shrinkage. There was no significant association of genotype at either of the TGFB1 SNPs with any measure of late radiation toxicity. CONCLUSION This adequately powered trial failed to confirm previously reported increases in fibrosis with TGFB1 genotype - any increase greater than 1.36 can be excluded with 95% confidence. Similar frequent failures to replicate associations with candidate genes have been resolved using genome-wide association scans: this methodology detects common, low risk alleles but requires even larger patient numbers for adequate statistical power.

[1]  M. Yokota,et al.  Association of a T29-->C polymorphism of the transforming growth factor-beta1 gene with genetic susceptibility to myocardial infarction in Japanese. , 2000, Circulation.

[2]  H. Ostrer,et al.  TGFB1 single nucleotide polymorphisms are associated with adverse quality of life in prostate cancer patients treated with radiotherapy. , 2008, International journal of radiation oncology, biology, physics.

[3]  M. Anscher,et al.  Does transforming growth factor-beta1 predict for radiation-induced pneumonitis in patients treated for lung cancer? , 2006, Cytokine.

[4]  S. Bentzen Preventing or reducing late side effects of radiation therapy: radiobiology meets molecular pathology , 2006, Nature Reviews Cancer.

[5]  K. Boda,et al.  The risk of early and late lung sequelae after conformal radiotherapy in breast cancer patients. , 2007, International journal of radiation oncology, biology, physics.

[6]  M. Dewhirst,et al.  Radiation-induced hypoxia may perpetuate late normal tissue injury. , 2001, International journal of radiation oncology, biology, physics.

[7]  J. Coggle,et al.  Expression of transforming growth factor-beta 1 in mouse skin during the acute phase of radiation damage. , 1995, International journal of radiation biology.

[8]  H. Groen,et al.  Transforming growth factor-beta plasma dynamics and post-irradiation lung injury in lung cancer patients. , 2004, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[9]  C. Coles,et al.  A randomised controlled trial of forward-planned radiotherapy (IMRT) for early breast cancer: baseline characteristics and dosimetry results. , 2009, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[10]  M. Dewhirst,et al.  Recent progress in defining mechanisms and potential targets for prevention of normal tissue injury after radiation therapy. , 2005, International journal of radiation oncology, biology, physics.

[11]  J. Chang-Claude,et al.  A Transforming Growth Factorβ1 Signal Peptide Variant Increases Secretion in Vitro and Is Associated with Increased Incidence of Invasive Breast Cancer , 2003 .

[12]  K. Cowan,et al.  Transforming growth factor-beta1 circulates in normal human plasma and is unchanged in advanced metastatic breast cancer. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[13]  J. Peacock,et al.  Why recent studies relating normal tissue response to individual radiosensitivity might have failed and how new studies should be performed. , 2003, International journal of radiation oncology, biology, physics.

[14]  J. Lefaix,et al.  The radiation-induced fibroatrophic process: therapeutic perspective via the antioxidant pathway. , 2004, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[15]  Mary Helen Barcellos-Hoff,et al.  Transforming growth factor-beta1 mediates cellular response to DNA damage in situ. , 2002, Cancer research.

[16]  J. Yarnold,et al.  The UK Standardisation of Breast Radiotherapy (START) Trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial , 2008, The Lancet. Oncology.

[17]  M. Anscher,et al.  Changes in plasma transforming growth factor beta during radiotherapy and the risk of symptomatic radiation-induced pneumonitis. , 1997, International journal of radiation oncology, biology, physics.

[18]  Alison M. Dunning,et al.  Normal tissue reactions to radiotherapy: towards tailoring treatment dose by genotype , 2009, Nature Reviews Cancer.

[19]  N G Burnet,et al.  Radiosensitivity, radiogenomics and RAPPER. , 2006, Clinical oncology (Royal College of Radiologists (Great Britain)).

[20]  N. Aaronson,et al.  The European Organization for Research and Treatment of Cancer breast cancer-specific quality-of-life questionnaire module: first results from a three-country field study. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  M. Barcellos-Hoff Integrative radiation carcinogenesis: interactions between cell and tissue responses to DNA damage. , 2005, Seminars in cancer biology.

[22]  H. Thames,et al.  Latent-time estimation for late cutaneous and subcutaneous radiation reactions in a single-follow-up clinical study. , 1989, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[23]  D. Tait,et al.  Evaluation of a method for grading late photographic change in breast appearance after radiotherapy for early breast cancer. , 2008, Clinical oncology (Royal College of Radiologists (Great Britain)).

[24]  C. Hurley,et al.  A molecular mechanism for the differential regulation of TGF-β1 expression due to the common SNP −509C-T (c. −1347C > T) , 2006, Human Genetics.

[25]  L. Le Marchand,et al.  Association of genetic variation in the transforming growth factor beta-1 gene with serum levels and risk of colorectal neoplasia. , 2008, Cancer research.

[26]  R. Clough,et al.  Predicting the risk of symptomatic radiation-induced lung injury using both the physical and biologic parameters V(30) and transforming growth factor beta. , 2001, International journal of radiation oncology, biology, physics.

[27]  J. Yarnold,et al.  TGFB1 polymorphisms are associated with risk of late normal tissue complications in the breast after radiotherapy for early breast cancer. , 2005, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[28]  T. Spector,et al.  Genetic control of the circulating concentration of transforming growth factor type beta1. , 1999, Human molecular genetics.

[29]  J. Alsner,et al.  Genetic variants and normal tissue toxicity after radiotherapy: a systematic review. , 2009, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[30]  J. Overgaard,et al.  Prediction of normal tissue radiosensitivity from polymorphisms in candidate genes. , 2003, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[31]  J R Yarnold,et al.  The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial , 2008, The Lancet.

[32]  J Nyman,et al.  Prognostic factors for acute and late skin reactions in radiotherapy patients. , 1996, International journal of radiation oncology, biology, physics.

[33]  M. Bissell,et al.  Ionizing radiation predisposes nonmalignant human mammary epithelial cells to undergo transforming growth factor beta induced epithelial to mesenchymal transition. , 2007, Cancer research.

[34]  S. Kumar,et al.  TGF‐β1 levels in pre‐treatment plasma identify breast cancer patients at risk of developing post‐radiotherapy fibrosis , 1999, International journal of cancer.

[35]  M. Martin,et al.  Coactivation of AP-1 activity and TGF-β1 gene expression in the stress response of normal skin cells to ionizing radiation , 1997, Oncogene.

[36]  F. B. Sørensen,et al.  Risk of radiation-induced subcutaneous fibrosis in relation to single nucleotide polymorphisms in TGFB1, SOD2, XRCC1, XRCC3, APEX and ATMndash; a study based on DNA from formalin fixed paraffin embedded tissue samples , 2006, International journal of radiation biology.

[37]  A. Hajeer,et al.  Association of transforming growth factor beta-1 single nucleotide polymorphisms with radiation-induced damage to normal tissues in breast cancer patients , 2003, International journal of radiation biology.

[38]  I. Turesson Individual variation and dose dependency in the progression rate of skin telangiectasia. , 1990, International journal of radiation oncology, biology, physics.

[39]  M. Plumb,et al.  The late radiotherapy normal tissue injury phenotypes of telangiectasia, fibrosis and atrophy in breast cancer patients have distinct genotype-dependent causes , 2007, British Journal of Cancer.

[40]  M. Barcellos-Hoff,et al.  Latent transforming growth factor β1 activation in situ: quantitative and functional evidence after low‐dose γ‐irradiation 1 , 1997, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[41]  H. Thierens,et al.  TGFbeta1 polymorphisms and late clinical radiosensitivity in patients treated for gynecologic tumors. , 2006, International journal of radiation oncology, biology, physics.